<DOC>
	<DOC>NCT02462603</DOC>
	<brief_summary>Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.</brief_summary>
	<brief_title>Safety and Biomarker Study of EPI-589 in Parkinson's Disease</brief_title>
	<detailed_description>This is a within-subject, controlled open-label study seeking to determine if EPI-589 can alter the biochemical signature of PD as assessed by peripheral blood and brain imaging biomarkers. Data will also be collected on disease-relevant clinical measures will be collected.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Hoehn and Yahr stage ≤ 2.5 Ambulatory with or without assistance Agreement to use contraception if within reproductive years Willingness and ability to comply with study procedures Stable regimen of dietary supplements for 30 days prior to enrollment Abstention from use of other investigative or nonapproved drugs for the duration of the trial For Idiopathic Subjects A diagnosis of early idiopathic PD confirmed by the presence of bradykinesia plus one or both of the following symptoms: rigidity or resting tremor; and with an abnormal DaTscan consistent with a dopaminergic deficit Must not yet require symptomatic medications for PD and not expected to require such treatment before the end of the study Age 40 to 75 years Within 5 years of diagnosis of Parkinson's disease For Genetic Subtype Subjects A confirmed diagnosis of PD plus a genetic diagnosis consistent with PD, specifically PINK1, parkin, LARK2 or other genetic subtype Age 21 to 75 years Stable medication regimen of PD drugs for 30 days (except 60 days for rasagiline) prior to enrollment Allergy to EPI589 or other components of the EPI589 tablet formulation Use of antioxidant supplements, specifically vitamins E and C beyond the recommended daily allowance Other Parkinsonian disorders MoCA score of &lt;24 Revised Hamilton Rating Scale for Depression ≥ 11 Parkinsonism due to drugs or toxins Diagnosis of any other clinically significant neurologic disease that will confound the assessment of effect of study drug on disease progression Malignancy within past two years Pregnant or plans to become pregnant or breast feeding History of stroke History of brain surgery Hepatic insufficiency with liver function tests (LFTs) &gt;3 times upper limit of normal Renal insufficiency as defined by creatinine &gt; 1.5 times normal End stage cardiac failure Participation within past 3 months and for duration of study in a trial of a device, drug or other therapy for PD For Idiopathic Subjects Use of any MAO inhibitors, amantadine or other drugs prescribed for core symptoms of Parkinson's disease for idiopathic subjects Use of nortriptyline or fluvoxamine 60 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>PD</keyword>
	<keyword>EPI-589</keyword>
	<keyword>EPI589</keyword>
</DOC>